Fluvoxamine Dosing
For adults, start fluvoxamine at 50 mg once daily at bedtime, then increase by 50 mg increments every 4-7 days as tolerated up to a maximum of 300 mg/day, with doses above 100 mg/day split into two divided doses (larger dose at bedtime). 1
Adult Dosing Algorithm
Initial Dosing:
- Start: 50 mg at bedtime
- Titration schedule: Increase by 50 mg every 4-7 days as tolerated
- Target therapeutic range: 100-300 mg/day
- Maximum dose: 300 mg/day
Dose Division:
- Doses ≤100 mg/day: Single dose at bedtime
- Doses >100 mg/day: Split into two divided doses, with the larger dose given at bedtime 1
The FDA labeling establishes this as the standard approach based on controlled trials in OCD that demonstrated efficacy within the 100-300 mg/day range 1. The 2020 AACAP guidelines note that fluvoxamine requires twice-daily dosing at any dose in youth, though adult pharmacokinetics may permit once-daily dosing at lower doses 2.
Pediatric Dosing (Ages 8-17)
Initial approach:
- Start: 25 mg at bedtime
- Titration: Increase by 25 mg every 4-7 days as tolerated
- Maximum for children ≤11 years: 200 mg/day
- Maximum for adolescents: 300 mg/day
- Doses >50 mg/day: Split into two divided doses (larger dose at bedtime) 1
Important consideration: Female children may achieve therapeutic effect at lower doses 1.
Special Populations
Elderly and hepatically impaired patients: Modify both initial dose and titration schedule due to decreased clearance 1. Start lower and titrate more slowly than standard dosing, though specific doses are not provided in the FDA labeling.
Titration Considerations
The 2020 AACAP guidelines recommend increasing doses at approximately 1-2 week intervals for shorter half-life SSRIs like fluvoxamine in mild-to-moderate anxiety, with faster titration acceptable for severe presentations 2. However, start with a subtherapeutic "test" dose if initial anxiety or agitation is a concern 2.
Research suggests that higher doses (100-150 mg/day) show significantly better response rates (73.7%) compared to lower doses (50-75 mg/day, 47.1% response) in depression, with most responders evident by 6 weeks 3. The minimum effective dose appears to be 50 mg/day 4.
Duration of Trial
Assess response at 6-8 weeks - if inadequate response, modify treatment 5. Most patients show maximal improvement by week 12 2. For maintenance, continue at the lowest effective dose with periodic reassessment 1.
Discontinuation
Taper gradually rather than stopping abruptly to minimize discontinuation syndrome (dizziness, nausea, fatigue, sensory disturbances, anxiety) 1, 2. Fluvoxamine is associated with discontinuation syndrome, though less prominently than paroxetine 2.
Critical Safety Warnings
Drug interactions: Fluvoxamine has extensive CYP450 interactions (1A2, 2C19, 2C9, 3A4, 2D6), creating greater potential for drug-drug interactions than other SSRIs 2. Exercise caution with alprazolam, triazolam, and other substrates of these enzymes 6, 2.
Monitor closely for suicidal ideation, especially in the first 1-2 weeks and after dose changes, given the FDA boxed warning for suicidality through age 24 2.
Avoid MAOIs - contraindicated due to serotonin syndrome risk 2.